Invitation | The 5th International Veterinary Testing and Diagnostics Conference – Weiboxin Biotechnology Looks Forward to Your Attendance

The 5th International Veterinary Testing and Diagnostic Conference will be held from June 24 to 26, 2024, at the Hangzhou International Expo Center, concurrently with the Asian Veterinary Devices and Pharmaceuticals Exhibition (AVDC). As Asia’s largest specialized conference in the field of veterinary testing and diagnostics, this event is committed to enhancing animal health and food safety through robust veterinary diagnostic services. On that occasion, Weiboxin, a manufacturer of diagnostic reagents for animal epidemics , while also possessing Molecular Diagnostic Products (Class B) and GMP Production Line for Immunological Diagnostic Products (Category B) will showcase a range of flagship products and solutions. We cordially invite all partners to attend, engage in exchanges and learning, and jointly explore opportunities for growth.

Exhibition Information

Date: June 24–26, 2024

Location: Hangzhou International Expo Center

Weiboxin Bio Booth No.: T139

Weiboxin Biotechnology cordially invites you to visit our booth T139 in Hall 3B. Thank you for your continued support!

When looking for animal disease testing reagents, choose the Weiboxin brand.

Be aware of Weiboxin Bio All products of!

Official consultation phone numbers: 020-66377266 / 135 3988 6748, Ms. Dai

Guangzhou Weiboxin Biotechnology Co., Ltd. is located in the national-level innovation park—Guangzhou Science City. The company is a provincial-level “Little Giant” high-tech enterprise specializing in the forward R&D, manufacturing, sales, and technical services of diagnostic reagents for animal epidemics. It has been recognized as a “Contract-Honoring and Credit-Keeping Enterprise” by Guangdong Province and as a “Provincial Intellectual Property Demonstration Unit.” Additionally, it serves as an industry–university–research collaboration base for Guangdong Food and Drug Vocational College and as an executive director unit of the Veterinary Diagnostic and Biological Products Committee of the Guangdong Society of Animal Husbandry and Veterinary Medicine. The company has been designated as an innovative, high-potential enterprise by multiple research institutions, including the Entrepreneurship College of Jinan University in Guangdong Province, and has been awarded the titles of “Specialized, Refined, Distinctive, and Innovative” enterprise at both municipal and provincial levels. It has also received the “Most Investment-Valuable Enterprise” award and the annual title of “ASF and Swine Disease Testing Service Provider.” Furthermore, its veterinary drug product has been granted an approval number by the Ministry of Agriculture and Rural Affairs—Veterinary Drug Production No. 191438923 (African Swine Fever Virus Fluorescent PCR Diagnostic Kit). The company won the Excellence Award in the Growth Category of the Biopharmaceutical Industry at the 11th China Innovation and Entrepreneurship Competition, secured the Provincial Second Prize in the Growth Category of the Nanotechnology Industry Technology Competition, and earned the National Third Prize in the Growth Category of the National Finals of the Nanotechnology Industry Technology Innovation Special Competition within the China Innovation and Entrepreneurship Competition. It has consecutively received the A-Level Tax Credit Honor Certificate, the Four-Star Trademark and Brand Certification, and the Two-Integration Management System Assessment Certificate each year. In addition, it holds ISO 9001 International Quality Management System Certification, ISO 14001 International Environmental Management System Certification, and GMP Certification from the Ministry of Agriculture. Since its establishment, the company has been granted a total of 24 patents, including 5 invention patents, 15 utility model patents, and 4 design patents, along with more than ten trademarks.

The company boasts robust technical capabilities and a team of world-class professionals, including dozens of masters, doctors, and returnees who studied abroad, as well as numerous senior-title technical experts. Currently, the company’s primary focus is on the research and development of molecular diagnostic reagents. Its core R&D team has developed more than 600 products spanning molecular diagnostics and immunoassays, including public-health–oriented fluorescent PCR test kits, animal disease–control–oriented fluorescent PCR test kits, clinical and research-grade fluorescent quantitative PCR kits, and transgenic identification test kits (ZL2006). The company has established a nationwide distribution network covering over ten major cities, such as Beijing, Shanghai, Hangzhou, Nanjing, Xi’an, Chongqing, Lanzhou, Zhengzhou, and Qingdao.

In its future development, Weiboxin will remain steadfast in its commitment to continuously enhance product quality and service standards. Leveraging a rapid and efficient research platform and abundant biomedical resources, the company will conduct extensive and in-depth R&D and scientific research in the biomedical field, thereby contributing to human health and advancing life sciences. Quality is our lifeline, and innovation is our soul; we will unwaveringly uphold this philosophy as we strive to become the premier supplier of rapid diagnostic reagents and instruments.